<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: After <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo> increases the risk of recurrence, <z:mp ids='MP_0001914'>hemorrhage</z:mp> and fatal <z:hpo ids='HP_0002181'>cerebral edema</z:hpo>, but blood pressure (BP) lowering in the <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> period is controversial due to fears of <z:mpath ids='MPATH_124'>infarct</z:mpath> extension and worsened outcomes </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: To determine whether BP lowering with <z:chebi fb="0" ids="3347">candesartan</z:chebi>, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of <z:hpo ids='HP_0000822'>hypertension</z:hpo> after experimental <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Male Wistar rats (280-305 g) underwent 3 h of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="3" pm="."><plain>At reperfusion, either saline (n = 18) or <z:chebi fb="0" ids="3347">candesartan</z:chebi> 1 mg/kg (n = 18) was administered intravenously </plain></SENT>
<SENT sid="4" pm="."><plain>BP was measured by telemetry for 2 days before and 24 h after MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>Neurologic function was assessed and sacrifice occurred at 24 h after occlusion </plain></SENT>
<SENT sid="6" pm="."><plain>Brain tissue was analyzed for <z:mpath ids='MPATH_124'>infarct</z:mpath> size, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content and <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Mean BP increased from 96 to 124 mmHg immediately upon MCAO and decreased to 114 mmHg after reperfusion, remaining elevated for 24 h (P &lt; 0.001) in the saline group </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="3347">Candesartan</z:chebi> reduced BP back to baseline and BP remained lower than in saline-treated animals until sacrifice (P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> size (54 versus 38%, P = 0.01) and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content (23.4 versus 10.0 microg/g tissue; P = 0.03) and <z:hpo ids='HP_0000969'>edema</z:hpo> (17.97 versus 11.33%, P &lt; 0.0001) were lower in the <z:chebi fb="0" ids="3347">candesartan</z:chebi> group </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, neurologic function at 24 h was improved (P = 0.0036) in the <z:chebi fb="0" ids="3347">candesartan</z:chebi> group </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="3347">Candesartan</z:chebi> administered after reperfusion in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> reduces neurovascular damage and improves outcome </plain></SENT>
</text></document>